Back to Search
STEFANIE HOLLENBACH, M.D.
M.D.
Obstetrics & Gynecology Physician
NPI: 1306289376IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Physician Assistant
Physician Assistant — Medical
Code: 363AM0700X
290009(NY)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
290009(NY)
Education
OTHER
Class of 2013
Research & Publications (20)
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.
PMID 19297154·Bioorg Med Chem Lett·2009
4-observational
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.
PMID 15013006·Bioorg Med Chem Lett·2004
7-preclinical
Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
PMID 15341941·Bioorg Med Chem Lett·2004
7-preclinical
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
PMID 15056002·J Med Chem·2004
7-preclinical
N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors.
PMID 15080981·Bioorg Med Chem Lett·2004
8-other
Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
PMID 14736451·J Am Coll Cardiol·2004
7-preclinical
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.
PMID 15013007·Bioorg Med Chem Lett·2004
7-preclinical
Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitors.
PMID 12639567·Bioorg Med Chem Lett·2003
7-preclinical
Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors.
PMID 12565972·Bioorg Med Chem Lett·2003
7-preclinical
Cleavage of in vitro and in vivo formed lens protein cross-links by a novel cross-link breaker.
PMID 12619891·Mol Cell Biochem·2003
8-other
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors.
PMID 12750119·Arterioscler Thromb Vasc Biol·2003
4-observational
Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.
PMID 12368212·Am J Pathol·2002
7-preclinical
Design, synthesis, and SAR of substituted acrylamides as factor Xa inhibitors.
PMID 12031331·Bioorg Med Chem Lett·2002
4-observational
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
PMID 12097282·Cancer Res·2002
7-preclinical
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
PMID 12166950·J Med Chem·2002
7-preclinical
Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.
PMID 12039584·Bioorg Med Chem Lett·2002
7-preclinical
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
PMID 12124172·Cancer Cell·2002
7-preclinical
Discovery of transition state factor Xa inhibitors as potential anticoagulant agents.
PMID 11899247·Curr Top Med Chem·2001
6-review
Design and synthesis of glycolic and mandelic acid derivatives as factor Xa inhibitors.
PMID 11527714·Bioorg Med Chem Lett·2001
7-preclinical
Characterization of hOGG1 promoter structure, expression during cell cycle and overexpression in mammalian cells.
PMID 11765003·Adv Exp Med Biol·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 601 ELMWOOD AVE
ROCHESTER, NY 14642 - Phone
- (585) 487-3350
Quick Facts
- NPI
- 1306289376
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 13
- Publications
- 20
Are you this provider?
Claim Your Profile